Anti-n3pglu amyloid beta peptide antibodies and uses thereof

The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are admi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Demattos, Ronald Bradley, Irizarry, Michael Carl
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	Demattos, Ronald Bradley Irizarry, Michael Carl
description	The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ772768A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ772768A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ772768A3</originalsourceid><addsrcrecordid>eNrjZLBxzCvJ1M0zLkjPKVVIzK3Myc9MUUhKLUlUKEgtKMlMSVVIBCpIyk_JTC0GMlMUSouBjJKM1KLU_DQeBta0xJziVF4ozc0g5-Ya4uyhm1qQH59aXJCYnJqXWhLvF2VubmRuZuFoTFABALoFLp8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anti-n3pglu amyloid beta peptide antibodies and uses thereof</title><source>esp@cenet</source><creator>Demattos, Ronald Bradley ; Irizarry, Michael Carl</creator><creatorcontrib>Demattos, Ronald Bradley ; Irizarry, Michael Carl</creatorcontrib><description>The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241129&DB=EPODOC&CC=NZ&NR=772768A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241129&DB=EPODOC&CC=NZ&NR=772768A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Demattos, Ronald Bradley</creatorcontrib><creatorcontrib>Irizarry, Michael Carl</creatorcontrib><title>Anti-n3pglu amyloid beta peptide antibodies and uses thereof</title><description>The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBxzCvJ1M0zLkjPKVVIzK3Myc9MUUhKLUlUKEgtKMlMSVVIBCpIyk_JTC0GMlMUSouBjJKM1KLU_DQeBta0xJziVF4ozc0g5-Ya4uyhm1qQH59aXJCYnJqXWhLvF2VubmRuZuFoTFABALoFLp8</recordid><startdate>20241129</startdate><enddate>20241129</enddate><creator>Demattos, Ronald Bradley</creator><creator>Irizarry, Michael Carl</creator><scope>EVB</scope></search><sort><creationdate>20241129</creationdate><title>Anti-n3pglu amyloid beta peptide antibodies and uses thereof</title><author>Demattos, Ronald Bradley ; Irizarry, Michael Carl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ772768A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Demattos, Ronald Bradley</creatorcontrib><creatorcontrib>Irizarry, Michael Carl</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Demattos, Ronald Bradley</au><au>Irizarry, Michael Carl</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anti-n3pglu amyloid beta peptide antibodies and uses thereof</title><date>2024-11-29</date><risdate>2024</risdate><abstract>The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_NZ772768A
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T13%3A16%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Demattos,%20Ronald%20Bradley&rft.date=2024-11-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ772768A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true